New Delhi: Zydus Lifesciences Ltd on Thursday said it has received tentative approval from the US health regulatory agency for its generic version of cancer treatment drug Ibrutinib tablets.
The Ibrutinib tablets will be produced at Zydus Lifesciences Ltd SEZ, Ahmedabad, it added.
The company said Ibrutinib is indicated for the treatment of adult patients with different types of blood cancers, Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM).
Citing IQVIA MAT May 2025, Zydus said Ibrutinib tablets had annual sales of USD 2148.9 million in the US.
'I Would Like...': Hardik Pandya Hints At Adding Another Star To Indian Jersey As He Prepares For Upcoming T20 World Cup; Video
Goa Nightclub Fire: CM Pramod Sawant Orders Demolition Of Vagator Beach Shack Owned By Absconding Luthra Brothers
MCC Extends NEET PG 2025 Round 2 Choice Filling Deadline To Dec 12; Check Details Here
Maharashtra Legislature’s Winter Session: Cash-Bomb Controversy Rocks State Assembly Over Viral Video Of Shinde Sena MLA Mahendra Dalvi Counting Notes
(Except for the headline, this article has not been edited by FPJ's editorial team and is auto-generated from an agency feed.)
